Latest Insights - page 52 | BiopharmaTrend

Benchling Acquires PipeBio to Enhance AI-Powered Antibody Discovery

Benchling, a cloud-based R&D software provider, has acquired PipeBio, a bioinformatics company specializing in high-throughput sequence analysis for biologics discovery. This collaboration brings together Benchling’s digital R&D tools with PipeBio’s …

Continue ›››

Laverock Therapeutics to Showcase New Data on Expanding Gene-Silencing Platform at ESGCT 2024

Following recent advancements in its gene-silencing technology, UK-based Laverock Therapeutics is set to present new data at the European Society of Gene & Cell Therapy (ESGCT) Conference in Rome, from …

Continue ›››

Life Biosciences Presents New Data on Epigenetic Reprogramming for Optic Neuropathies at AAO 2024

Life Biosciences, a biotech company advancing therapies to reverse aging-related diseases, shared new findings at the American Academy of Ophthalmology (AAO) Annual Meeting, held from October 18-21, 2024, in Chicago. …

Continue ›››

Beyond Traditional Clinical Trials: MEDSIR’s Adaptive Designs and Precision Medicine in Oncology

Recursion Begins Phase 2 Trial for AI-Developed Non-Antibiotic Treatment for Recurrent C. diff. Infection

Recursion, an AI-driven drug discovery company, has dosed the first patient in its Phase 2 ALDER trial for REC-3964, an oral small molecule for the treatment of recurrent Clostridioides difficile …

Continue ›››

Combatting Antibiotic Resistance: Global Superbug Map Supports Phage Therapy Development

A new global "superbug map" has been developed to track the spread of Acinetobacter baumannii, a critically antibiotic-resistant species often found in hospitals. This map, published in Cell, was created …

Continue ›››

Univercells Technologies Introduces the Scale-X Nexo Bioreactor for Enhanced Cell Culture Process Development

Univercells Technologies by Donaldson has launched the scale-X nexo bioreactor, a new addition to its scale-X portfolio, designed to support efficient cell culture process development across multiple modalities.

Continue ›››

British Patient Capital Invests £8M in Nuclera as Part of $75M Series C Funding

British Patient Capital has announced an £8 million investment in biotechnology company Nuclera, contributing to a $75 million Series C financing round. The round was led by Elevage Medical Technologies, …

Continue ›››

First Human Skin Map Could Aid in Regenerative Medicine and Scar Prevention

Researchers from the Wellcome Sanger Institute, Newcastle University, and their collaborators have created a detailed single-cell atlas of prenatal human skin. The study, published today in Nature, provides new insights …

Continue ›››

clock.bio Secures $5.3M Seed Funding, Decodes Genetic Atlas of Human Rejuvenation Factors

clock.bio, a biotech company leveraging stem cell biology to extend human healthspan, has raised $5.3 million in seed funding. The round, led by LocalGlobe with participation from BlueYard Capital, Onsight …

Continue ›››

Evaxion's AI-Immunology Platform Gains Validation in Clinical Trials

Evaxion Biotech has achieved a notable breakthrough with its AI-Immunology platform, demonstrating its capability to select effective cancer vaccine targets in clinical trials. This AI-powered platform, integrating proprietary models like …

Continue ›››

Pfizer Joins Forces with Ignition AI Accelerator to Boost AI-Driven Drug Discovery in Southeast Asia

Pfizer has entered into a partnership with the Ignition AI Accelerator to integrate artificial intelligence (AI) into its drug discovery and development efforts. This collaboration is designed to accelerate the …

Continue ›››